- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01221610
BIOLUX P-I First in Man Study
February 6, 2015 updated by: Biotronik AG
A Prospective, Multi-centre, Randomized Controlled, First in Man Study to Assess the Safety and Performance of the Passeo-18 Lux Paclitaxel Releasing PTA Balloon Catheter vs. the Uncoated Passeo 18 Balloon Catheter in Patients With Stenosis and Occlusion of the Femoropopliteal Arteries (BIOLUX P-I).
A prospective, multi-centre, randomized controlled, First in Man study to assess the safety and performance of the coated Passeo-18 Lux Paclitaxel releasing PTA Balloon Catheter vs. an uncoated balloon catheter in patients with stenosis and occlusion of the femoropopliteal arteries.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Vienna, Austria
- AKH Wien, Kardiovaskuläre und Interventionelle Radiologie
-
-
-
-
-
Bad Krozingen, Germany
- Universitäts-Herzzentrum Freiburg Bad Krozingen
-
Berlin, Germany
- Gefaesszentrum Berlin, Medizinische Klinik, Ev. Krankenhaus Königin Elisabeth Herzberge
-
Leipzig, Germany
- Parkkrankenhaus Leipzig Südost GmbH
-
Rosenheim, Germany
- Institut für diagnostische und interventionelle Radiologie, Klinikum Rosenheim
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 50 years,
- Informed consent signed by patient prior to randomization
- Single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction or occlusion) in the femoropopliteal arteries ≥ 30 mm and ≤ 200 mm long
- Rutherford Class 2 - 5 in the target limb
- Reference Vessel Diameter (RVD) 3 - 7 mm, based on visual estimation
- Inflow free from flow-limiting lesion (< 50% stenosis) confirmed by angiography. Patients with flow-limiting inflow lesions (> 50% stenosis) can be included if lesion has been treated successfully before the index procedure
- At least one non-occluded crural vessel (eg without significant stenosis) with angiographically documented run-off to the foot
- Successful wire crossing of the lesion
- Willingness to comply with all specified follow-up evaluations
- Male or negative pregnancy test of women in childbearing age
Exclusion Criteria:
- Co-morbid conditions limiting life expectancy ≤ 1 year
- Patient currently participating in another clinical trial
- Lesions which are untreatable with PTA or other interventional techniques
- The target stenosis is located distal to a stenosis ≥ 50% that cannot be pre-treated because the drug coating could get lost during crossing the proximal lesion
- Thrombus in the target vessel, documented by angiography
- Target lesion is severely calcified, documented by angiography
- Prior bypass surgery of target vessel
- Previously implanted stent in the target lesion
- Treatment of bifurcation required
- Planned amputation of the target limb
- Flow-limiting (> 50% DS) Inflow lesion proximal to target lesion, left untreated
- Failure to obtain <30% residual stenosis in a pre-existing haemodynamically significant (>50% DS) inflow lesion in the ipsilateral iliac or proximal SFA. (DEB or DES not allowed for the treatment of inflow lesion)
- Additional hemodynamically relevant proximal and distal lesions with stenosis ≥ 50 %, except iliac arteries, are excluded. Iliac artery lesion treatments have to be successful with a residual stenosis ≤ 30 %
- Haemorrhagic diathesis or another disorder such as gastrointestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anticoagulation therapy
- Phenprocoumon intake
- Impaired renal function (creatinine ≥ 2.0 - 2.5 mg/dl), according to investigator assessment
- Known allergy to contrast media that cannot be adequately controlled with pre-medication
- Allergy, intolerance or hypersensitivity to Paclitaxel structurally or related compounds and/or to the delivery matrix n-Butyryl tri-nhexyl citrate (BTHC)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug Releasing Balloon
Passeo-18 Lux Drug Releasing Balloon catheter
|
Other Names:
|
Active Comparator: Standard PT A (POBA)
Uncoated Passeo-18 PTA catheter
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of the 6 months late lumen loss in the target lesion measured by quantitative vascular angiography (QVA).
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
6 months binary restenosis rate
Time Frame: 6 months
|
6 months
|
6 months and 12 months TLR rate
Time Frame: 6 and 12 months
|
6 and 12 months
|
6 months and 12 months change in mean ABI
Time Frame: 6 and 12 months
|
6 and 12 months
|
6 months and 12 months change in Rutherford class
Time Frame: 6 and 12 months
|
6 and 12 months
|
Major Adverse Event rate at 6 and 12 months (procedure- or device-related death or amputation, target lesion thrombosis and clinically driven TLR)
Time Frame: 6 and 12 months
|
6 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dierk Scheinert, MD, Park-Krankenhaus Leipzig GmbH, Leipzig, Germany
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
January 1, 2013
Study Registration Dates
First Submitted
October 14, 2010
First Submitted That Met QC Criteria
October 14, 2010
First Posted (Estimate)
October 15, 2010
Study Record Updates
Last Update Posted (Estimate)
February 9, 2015
Last Update Submitted That Met QC Criteria
February 6, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C1003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arteriosclerosis
-
Daewoong Pharmaceutical Co. LTD.CompletedArteriosclerosis ObliteransKorea, Republic of
-
Jun-min BaoUnknownArteriosclerosis; ExtremitiesChina
-
Kansai Rosai HospitalAssociation for Establishment of Ebvidence in InterventionsUnknownArteriosclerosis ObliteransJapan
-
GE HealthcareTurku University Hospital; University of Turku; The Finnish Funding Agency for...CompletedArteriosclerosis ObliteransFinland
-
Region Örebro CountyRecruitingCoronary Stenosis | Calcific Coronary ArteriosclerosisSweden
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDUnknownArteriosclerosis ObliteransChina
-
Medtronic CardiovascularCompletedArteriosclerosis of Coronary Artery Bypass GraftCanada, United States
-
Cordis CorporationCompletedCoronary Arteriosclerosis | Angioplasty, Transluminal, Percutaneous Coronary | Peripheral ArteriosclerosisUnited States
-
Johns Hopkins UniversityNorthwestern UniversityCompletedCoronary Artery Disease | Coronary Arteriosclerosis | Coronary Atherosclerosis | Atherosclerosis, Coronary | Arteriosclerosis, CoronaryUnited States
-
University of VermontNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Coronary Disease | Atherosclerosis | Coronary Arteriosclerosis | Cerebrovascular Accident | Cerebral Arteriosclerosis
Clinical Trials on Passeo-18 Lux DRB
-
Biotronik AGCompletedArteriosclerosis | Atherosclerosis | Peripheral Artery Disease | Vascular DiseaseBelgium, Austria, Germany
-
Biotronik AGCompleted
-
Singapore General HospitalUnknownHemodialysis Access Failure | Dialysis Access Malfunction | Arterio-venous Fistula | Arteriovenous Graft StenosisSingapore
-
Flanders Medical Research ProgramCompletedPeripheral Vascular DiseaseBelgium
-
Singapore General HospitalCompletedBrachiocephalic Vein StenosisSingapore
-
ID3 MedicalActive, not recruitingPeripheral Arterial DiseaseBelgium, Austria, France, Switzerland
-
Biotronik AGCompletedAtherosclerosis | Peripheral Artery DiseaseFrance, Germany, Spain, Belgium, Singapore, Austria, Netherlands, Malaysia, Italy, Switzerland, Denmark, Portugal, Australia, Finland, Latvia, Slovakia
-
Biotronik AGCompletedPeripheral Arterial DiseaseNetherlands, Belgium, Luxembourg
-
Centre hospitalier de l'Université de Montréal...Biotronik Canada IncCompletedArteriovenous Graft | Arteriovenous FistulaeCanada